SenesTech Aktie Logo
US81720R5054
A3EVGZ
SNES

SenesTech Aktie

Chargement des cours...

Prévisions

Acheter
  2
Conserver
  0
Vendre
  0

  • SenesTech reports record figures and accelerated turnaround after realignment

    At the Lytham Partners Summit, SenesTech presented an operational realignment completed in about 200 days that led to record revenues, record gross profits and improved margins for the quarter. E‑commerce revenues nearly tripled, subscription revenues nearly doubled, and the company reduced monthly cash burn, bringing cash‑flow breakeven into view. Management is building two growth engines — a restructured e‑commerce business and a structured B2B sales organization — and sees scaling potential without substantial additional investment. » Plus sur de.investing.com


  • SenesTech launches distribution of Evolve birth control in Bermuda

    SenesTech has signed a distribution agreement with Animal and Garden House to introduce its Evolve rodent birth-control product in Bermuda. The product aims to reduce rodent populations through fertility control instead of lethal rodenticides and can supplement or replace existing pest-control programs. The expansion, CEO Michael Edell said, aligns with Bermuda’s environmental protection focus; the company is already active in the U.S. Virgin Islands and Belize. SenesTech most recently reported a market capitalization of $8.16 million, annual revenue of $2.23 million and growth of 15.67%, while analysts note undervaluation and increased cash burn associated with the expansion. » Plus sur de.investing.com


  • SenesTech increases Q1 revenue slightly to $493,000, gross margin reaches record

    SenesTech reported a 2% revenue increase in the first quarter of 2026 to $493,000 and a record gross margin of 68.6%. Direct management of the Amazon account led to a 42% rise in D2C revenue; subscription revenues grew 44%. Management sees long-term benefits from the sales shift and expansion of the subscription model, but warned of short-term revenue disruptions. The stock fell about 4% in premarket trading. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, SenesTech Aktie a réalisé un chiffre d'affaires de 674,68 k € et un bénéfice net de -1,61 M €
(EUR) juin 2026
YoY
Chiffre d'affaires 674,68 k 27,24 %
Bénéfice brut 496,81 k 43,17 %
Bénéfice net -1,61 M 17,08 %
EBITDA -1,57 M 17,77 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
5,03 M €
Nombre d'actions
5,3 M
Plus haut/bas sur 52 semaines
4,61 € - 0,91 €
Dividendes Non
Bêta
0,26
Ratio P/E
-0,80
Ratio PEG
0,00
Ratio P/B
0,96
Ratio P/S
2,46

Profil de l'entreprise

SenesTech, Inc. entwickelt eine Technologie zur Kontrolle von Tierschädlingspopulationen durch Fruchtbarkeitskontrolle. Es bietet ContraPest an, einen Flüssigköder, der die Fortpflanzung von männlichen und weiblichen Ratten einschränkt. Das Unternehmen wurde im Jahr 2004 gegründet und hat seinen Hauptsitz in Phoenix, Arizona.

Nom
SenesTech Aktie
PDG
Michael Edell
Siège social Surprise, az
États-Unis
Site web
Industrie
Produits chimiques
Introduction en bourse
08/12/2016
Employés 24

Symboles boursiers

Bourse Symbole
NASDAQ
SNES
Frankfurt
SE81.F
🍪

Parqet  utilise des cookies. En savoir plus